What does this research mean for the field?

Phytochemicals may offer cardioprotective properties against doxorubicin-induced cardiotoxicity, but face challenges like low bioavailability and dose-dependent toxicity. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to explore the cardioprotective effects of phytochemicals against doxorubicin-induced cardiotoxicity.

February 12, 2026Drug Metabolism Reviews

Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies

View Full Paper

Ask AI

Bookmark

Key result

Phytochemicals offer preclinical cardioprotection against doxorubicin toxicity but face clinical bioavailability and safety limitations.

Why the study?

Doxorubicin causes dose-dependent cardiotoxicity, and concerns over dexrazoxane's long-term safety and potential interference with antitumor effectiveness have driven the search for safer cardioprotective alternatives.

Do phytochemicals and herbal compounds provide effective cardioprotection against doxorubicin-induced cardiotoxicity?

Comparison

Phytochemicals and herbal compounds targeting key signalling pathways in doxorubicin-induced cardiotoxicity

Authors

MSMukul ShyamVellore Institute of Technology University AMAmrutha MVellore Institute of Technology University NKNiharika KommojuVellore Institute of Technology University

Discussion

Member takes

Implication

Does not yet support clinical use of phytochemicals against doxorubicin cardiotoxicity; leaves open optimized delivery in future trials.

Key Points

The aim is to explore the cardioprotective effects of phytochemicals against doxorubicin-induced cardiotoxicity.
Investigated key signalling pathways affected by doxorubicin.
Analyzed the cardioprotective effects of various phytochemicals and herbal compounds.
Discussed challenges such as bioavailability and dose-dependent toxicity.
Phytochemicals showed potential antioxidant, anti-inflammatory, and anti-apoptotic effects.
Clinical use is hindered by low bioavailability and lack of standardisation.
Innovative delivery systems and formulations are necessary for enhancing effectiveness.

Structured PICO

Do phytochemicals and herbal compounds provide effective cardioprotection against doxorubicin-induced cardiotoxicity?

Intervention

Phytochemicals and herbal compounds

While phytochemicals show preclinical promise for preventing doxorubicin-induced cardiotoxicity, innovative delivery systems are needed to overcome significant pharmacological barriers to clinical use.

Limitations

low bioavailability
poor specificity
dose-dependent toxicity
variable pharmacokinetics
lack of standardisation

Cite This Study

Shyam et al. (2026) studied this question. Phytochemicals show preclinical cardioprotection against doxorubicin toxicity via key pathways but face clinical limitations like low bioavailability and safety concerns.

synapsesocial.com/papers/698d6e1a5be6419ac0d5375a https://doi.org/10.1080/03602532.2026.2627345

View Full Paper

Ask AI

Bookmark

Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider